Table 1.
Characteristics of the study population before cerebrospinal fluid biomarker diagnosis
| Study population | BNA population | BNA/study population comparison | |||||
|---|---|---|---|---|---|---|---|
| Overall | Psychiatric disorder | p Value | Overall | Psychiatric disorder | p value | p Value | |
| Number of patients | 1015 | 69 (6.79) | 317,515 | 24,561 (7.74) | 0.29 | ||
| Age, years, mean (SD) | 69.2 (10.03) | 64.57 (11.57) | 0.0018 | 76.86 (12.18) | 71.43 (13.82) | <0.0001 | <0.0001 |
| Female sex, n (%) | 504 (49.7) | 43 (61.4) | 0.056 | 199,085 (62.7) | 17,661 (71.91) | <0.0001 | 0.46 |
| Final diagnosis of AD, n (%) | 395 (38.9) | 13 (18.8) | 0.009 | 70,651 (22.25) | 536 (2.18) | <0.0001 | <0.0001 |
| Changed diagnosis, n (%) | 231 (24.1) | 19 (27.5) | 0.62 | 1821 (7.41) | <0.0001 | ||
| Improvement in diagnosis confidence level, % | 19.6 | 25.2 | 0.027 | ||||
| Changed treatment, n (%) | 437 (43.1) | 24 (34.8) | 0.13 | ||||
AD Alzheimer’s disease, BNA Banque Nationale Alzheimer